Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab for Chronic, Severe ITP in Children
NCT01713738Phase 2Completed
- Start
- May 2003
- Primary completion
- Dec 2005
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rituximab in immune thrombocytopenia (ITP). Primary endpoints: Platelet levels and Hypogammaglobulinemia at 1 year. Started May 2003; status: completed.
02
Drugs
rituximab
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on NCT01713738.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01713738.